Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSD
Dates
study started
study ends around
Principal Investigator
by Ulrika Birgersdotter-Green (ucsd)

Description

Summary

Non-invasive vagus nerve stimulation has been clinically tested for the treatment cardiac arrhythmias. However, prior studies have shown mixed results-possibly in part due to inadequate stimulation duration. Therefore, we have designed an investigator-initiated early feasibility study to evaluate safety, tolerability, and compliance with prolonged, nocturnal auricular nerve stimulation using the Parasym device.

Details

The study will utilize the Parasym transcutaneous auricular vagal nerve stimulation device. This small, battery-powered device delivers electrical stimulation through an ear clip attached to the tragus. Participants will self-administer the stimulation once daily, at bedtime, for 6 continuous hours. The device has two settings to facilitate our RCT: active treatment and sham control. After one month in the first treatment arm, participants will be crossed over to the other arm of the study. Participants and outcome assessors will be blinded to the allocation. The primary outcomes will be assessed via standardized questionnaires administered by blinded outcome assessors. The secondary outcome of PVC burden will be assessed by non-invasive event monitors.

Keywords

Premature Ventricular Complexes, PVC - Premature Ventricular Contraction, Auricular Vagus Nerve Stimulation, parasym, premature ventricular contractions (PVCs), Non-invasive neuromodulation, Cardiac arrhythmia, autonomic nervous system modulation, Trancutaneous electrical stimulation, Randomized controlled trial, heart rate variability, feasibility study, Ventricular Premature Complexes, Cardiac Arrhythmias, Extended nocturnal use of auricular vagus nerve stimulator device

Eligibility

You can join if…

Open to people ages 18 years and up

Individuals must meet all of the following inclusion criteria to be eligible to participate in this study:

Age ≥ 18 years

PVC burden ≥ 10% documented on an event monitor or implanted cardiac device

Provide written informed consent

Willingness to comply with all study procedures

Availability for the duration of the study (10 weeks)

Individuals meeting any of the following

You CAN'T join if...

at baseline will be excluded from study participation:

Unwilling or unable to provide informed consent for oneself

Last available left ventricular ejection fraction < 20%

NYHA Class IV symptoms

Acute coronary syndrome within two weeks of randomization

Active pregnancy or breastfeeding

Intention to become pregnant

Statement Regarding Equitable Selection:

This study will not exclude specific populations based on age, sex, race, or ethnicity. The inclusion/exclusion criteria are based on clinical factors relevant to the study intervention and the safety of participants. Limited English proficiency will not be an exclusion criterion, and appropriate translation services will be provided to ensure informed consent and understanding of study procedures.

Location

  • UC San Diego Health System
    La Jolla 5363943 California 5332921 92037 United States

Lead Scientist at University of California Health

Details

Status
accepting new patients by invitation only
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Diego
ID
NCT07093034
Study Type
Interventional
Participants
Expecting 16 study participants
Last Updated